Please Wait.....
Report
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030
Market Report I 2024-09-17 I 291 Pages I MarketsandMarkets
The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.
Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
"The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023."
The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.
"The Asia Pacific region is growing at the highest CAGR in the human microbiome market from 2024 to 2030."
The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high - throughout sequencing technologies has made it possible to sequence the entire mircrobiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human mircrobiomes, are expected to restrain the growth of the Asia- pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain region, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Executives - 25%, CXOs - 30%, and Managers - 45%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa -5%..
List of Companies Profiled in the Report:
- Nestle S.A. (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- BiomeBank (Australia)
- Seed Health, Inc. (US)
- International Flavors & Fragrances Inc (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Actial Farmaceutica SRL (Italy)
- Optibiotix Health plc (UK)
- Resbiotic (US)
- Infinant Health Inc (US)
- Biogaia AB (Sweden)
- Exegi Pharma Llc (US)
Research Coverage:
This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the Human Microbiome market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market
- Competitive Assessment: Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 30
1.3 STUDY SCOPE 30
1.3.1 MARKET SEGMENTATION 30
1.4 YEARS CONSIDERED 31
1.5 CURRENCY 31
1.6 RESEARCH LIMITATIONS 31
1.7 STAKEHOLDERS 31
1.8 SUMMARY OF CHANGES 32
1.9 IMPACT OF AI/GEN AI 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
2.2 MARKET ESTIMATION METHODOLOGY 36
2.2.1 MARKET ESTIMATION 36
2.2.1.1 Insights of primary experts 38
2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 42
2.5 RESEARCH ASSUMPTIONS 43
2.6 LIMITATIONS 43
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 HUMAN MICROBIOME MARKET OVERVIEW 48
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT AND COUNTRY (2023) 49
4.3 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2030) 49
?
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
5.2.1 DRIVERS 51
5.2.1.1 Collaborative initiatives between organizations and academia in microbiome industry 51
5.2.1.2 Increasing number of start-ups/SMEs exploring microbiome niche 53
5.2.1.3 Advancements in microbiome sequencing 54
5.2.2 RESTRAINTS 54
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes 54
5.2.2.2 High investments in commercialization of microbiome drugs 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Increasing demand for personalized medicine 56
5.2.3.2 Emergence of postbiotics 57
5.2.4 CHALLENGES 57
5.2.4.1 Slow patient adoption of microbiome-based therapies 57
5.2.4.2 Complexities involved in development of microbiome therapies 58
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 58
5.4 PRICING ANALYSIS 59
5.4.1 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER 59
5.4.2 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021-2023 60
5.4.3 AVERAGE SELLING PRICE ANALYSIS, BY REGION 61
5.5 PIPELINE ANALYSIS 62
5.6 PATENT ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 65
5.8 SUPPLY CHAIN ANALYSIS 66
5.9 VALUE CHAIN ANALYSIS 67
5.10 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 68
5.11 TECHNOLOGY ANALYSIS 70
5.11.1 KEY TECHNOLOGIES 70
5.11.1.1 Whole-genome sequencing 70
5.11.1.2 16s RNA sequencing method 71
5.11.1.3 Nanopore sequencing 71
5.11.2 COMPLEMENTARY TECHNOLOGIES 71
5.11.2.1 Metatranscriptomics 71
5.11.2.2 Metagenomics 72
5.11.2.3 Metabolomics 72
5.11.3 ADJACENT TECHNOLOGIES 73
5.11.3.1 Sample preparation 73
5.11.3.2 Data analysis 73
5.11.3.3 Library synthesis 73
5.12 KEY CONFERENCES & EVENTS IN 2024-2025 74
5.13 REGULATORY ANALYSIS 76
5.13.1 REGULATORY LANDSCAPE 76
5.13.1.1 North America 76
5.13.1.2 Europe 77
5.13.1.3 Asia Pacific 78
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
5.14 PORTER'S FIVE FORCES ANALYSIS 84
5.14.1 THREAT OF NEW ENTRANTS 85
5.14.2 THREAT OF SUBSTITUTES 85
5.14.3 BARGAINING POWER OF BUYERS 86
5.14.4 BARGAINING POWER OF SUPPLIERS 86
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 87
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.15.2 BUYING CRITERIA 88
5.16 CASE STUDY ANALYSIS 88
5.16.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION 88
5.16.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION 88
5.16.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS. 89
5.17 INVESTMENT & FUNDING SCENARIO 89
5.17.1 OTHER INVESTMENTS AND FUNDING 93
6 HUMAN MICROBIOME MARKET, BY PRODUCT 95
6.1 INTRODUCTION 96
6.2 DRUGS 96
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET 96
6.3 PROBIOTICS 97
6.3.1 GROWING CONSUMER AWARENESS ABOUT PROBIOTICS FOR IMPROVED GUT HEALTH AND IMMUNITY TO AID MARKET GROWTH 97
6.4 PREBIOTICS 100
6.4.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH 100
6.5 SYNBIOTICS 103
6.5.1 GROWING DEMAND FOR PERSONALIZED TREATMENT AND RISING INCIDENCE OF DYSBIOSIS TO AUGMENT MARKET GROWTH 103
?
7 HUMAN MICROBIOME MARKET, BY DISEASE 106
7.1 INTRODUCTION 107
7.2 INFECTIOUS DISEASES 107
7.2.1 EMERGENCE OF MULTI-DRUG-RESISTANT BACTERIA TO BOOST MARKET GROWTH 107
7.3 GASTROINTESTINAL DISEASES 109
7.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO PROPEL MARKET GROWTH 109
7.4 ENDOCRINE & METABOLIC DISORDERS 111
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET GROWTH 111
7.5 OTHER DISEASES 115
8 HUMAN MICROBIOME MARKET, BY TYPE 118
8.1 INTRODUCTION 119
8.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 119
8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH 119
8.3 LIVE BIOTHERAPEUTIC PRODUCTS (LBP) 122
8.3.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET 122
8.4 OTHER MICROBIOME TYPES 125
9 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION 129
9.1 INTRODUCTION 130
9.2 ORAL ROUTE OF ADMINISTRATION 130
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO DRIVE MARKET GROWTH 130
9.3 RECTAL ROUTE OF ADMINISTRATION 133
9.3.1 PRODUCT APPROVALS AND EFFICACY IN TARGETED DELIVERY TO SUPPORT MARKET GROWTH 133
10 HUMAN MICROBIOME MARKET, BY END USER 136
10.1 INTRODUCTION 137
10.2 HOSPITALS & CLINICS 137
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH 137
10.3 LONG-TERM CARE FACILITIES 140
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET 140
10.4 OTHER END USERS 143
?
11 HUMAN MICROBIOME MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 147
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 150
11.2.2 US 151
11.2.2.1 Strong ecosystem backed by regulation, research,
and funding to drive market 151
11.2.3 CANADA 153
11.2.3.1 Government initiatives, independent organizations,
and academia collaborations to boost microbiome research 153
11.3 EUROPE 156
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 158
11.3.2 GERMANY 159
11.3.2.1 Rapid increase in government and private funding to propel market 159
11.3.3 UK 161
11.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth 161
11.3.4 FRANCE 163
11.3.4.1 Growing awareness and rise of specialized organizations
to boost growth 163
11.3.5 ITALY 166
11.3.5.1 Government intervention and academic institutions
to drive market growth 166
11.3.6 SPAIN 168
11.3.6.1 Growing academic research initiatives to boost growth 168
11.3.7 REST OF EUROPE 170
11.4 ASIA PACIFIC 172
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 175
11.4.2 CHINA 176
11.4.2.1 Increasing R&D investments to drive growth 176
11.4.3 JAPAN 178
11.4.3.1 Growing geriatric population to present opportunities
for market growth 178
11.4.4 INDIA 181
11.4.4.1 Increasing prevalence of chronic diseases to support growth 181
11.4.5 SOUTH KOREA 183
11.4.5.1 Increasing prevalence of chronic diseases to support growth 183
11.4.6 AUSTRALIA 185
11.4.6.1 Growing number of product approvals to boost growth 185
11.4.7 REST OF ASIA PACIFIC 187
?
11.5 LATIN AMERICA 189
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 191
11.5.2 BRAZIL 192
11.5.2.1 Rising probiotics demand to drive market 192
11.5.3 REST OF LATIN AMERICA 194
11.6 MIDDLE EAST 196
11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 198
11.6.2 GCC COUNTRIES 199
11.6.2.1 Saudi Arabia 201
11.6.2.1.1 Increasing focus on R&D to boost market growth 201
11.6.2.2 UAE 203
11.6.2.2.1 Increasing focus on R&D and healthcare spending to boost market growth 203
11.6.2.3 Rest of GCC countries 205
11.6.3 REST OF MIDDLE EAST 207
11.7 AFRICA 209
11.7.1 STUDIES AND INITIATIVES TO BOOST MARKET GROWTH 209
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 211
12 COMPETITIVE LANDSCAPE 213
12.1 INTRODUCTION 213
12.1.1 KEY PLAYER STRATEGY/RIGHT TO WIN 213
12.1.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
IN HUMAN MICROBIOME MARKET 213
12.2 REVENUE ANALYSIS, 2021-2023 215
12.3 MARKET SHARE ANALYSIS, 2023 217
12.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 220
12.4.1 STARS 220
12.4.2 EMERGING LEADERS 220
12.4.3 PERVASIVE PLAYERS 220
12.4.4 PARTICIPANTS 220
12.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 222
12.4.5.1 Company footprint 222
12.4.5.2 Product footprint 223
12.4.5.3 Type footprint 224
12.4.5.4 Disease footprint 225
12.4.5.5 Region footprint 226
12.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 226
12.5.1 PROGRESSIVE COMPANIES 226
12.5.2 RESPONSIVE COMPANIES 226
12.5.3 DYNAMIC COMPANIES 227
12.5.4 STARTING BLOCKS 227
12.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 228
12.6 COMPANY VALUATION & FINANCIAL METRICS 230
12.7 BRAND/PRODUCT COMPARISON 231
12.8 COMPETITIVE SCENARIO 233
12.8.1 PRODUCT APPROVALS 233
12.8.2 DEALS 234
13 COMPANY PROFILES 235
13.1 KEY PLAYERS 235
13.1.1 INTERNATIONAL FLAVORS & FRAGRANCES, INC. 235
13.1.1.1 Business overview 235
13.1.1.2 Products offered 236
13.1.1.3 Recent developments 238
13.1.1.3.1 Deals 238
13.1.1.4 MnM view 239
13.1.1.4.1 Key strengths 239
13.1.1.4.2 Strategic choices 239
13.1.1.4.3 Weaknesses & competitive threats 239
13.1.2 SEED HEALTH, INC. 240
13.1.2.1 Business overview 240
13.1.2.2 Products offered 240
13.1.2.3 Recent developments 241
13.1.2.3.1 Deals 241
13.1.2.4 MnM view 242
13.1.2.4.1 Key strengths 242
13.1.2.4.2 Strategic choices 242
13.1.2.4.3 Weaknesses & competitive threats 242
13.1.3 PENDULUM 243
13.1.3.1 Business overview 243
13.1.3.2 Products offered 244
13.1.3.3 Recent developments 244
13.1.3.3.1 Deals 244
13.1.3.4 MnM view 245
13.1.3.4.1 Key strengths 245
13.1.3.4.2 Strategic choices 245
13.1.3.4.3 Weaknesses & competitive threats 245
13.1.4 SERES THERAPEUTICS 246
13.1.4.1 Business overview 246
13.1.4.2 Products offered 247
13.1.4.3 Recent developments 247
13.1.4.3.1 Product approvals 247
13.1.4.3.2 Deals 248
?
13.1.4.4 MnM view 249
13.1.4.4.1 Key strengths 249
13.1.4.4.2 Strategic choices 249
13.1.4.4.3 Weaknesses & competitive threats 249
13.1.5 FERRING PHARMACEUTICALS 250
13.1.5.1 Business overview 250
13.1.5.2 Products offered 251
13.1.5.3 Recent developments 252
13.1.5.3.1 Product approvals 252
13.1.5.3.2 Deals 252
13.1.5.4 MnM view 253
13.1.5.4.1 Key strengths 253
13.1.5.4.2 Strategic choices 253
13.1.5.4.3 Weaknesses & competitive threats 253
13.1.6 BIOMEBANK 254
13.1.6.1 Business overview 254
13.1.6.2 Products offered 254
13.1.6.3 Recent developments 255
13.1.6.3.1 Product approvals 255
13.1.6.3.2 Expansions 255
13.1.7 BIOHM HEALTH INC. 256
13.1.7.1 Business overview 256
13.1.7.2 Products offered 256
13.1.7.3 Recent developments 258
13.1.7.3.1 Deals 258
13.1.8 ACTIAL FARMACEUTICA SRL 259
13.1.8.1 Business overview 259
13.1.8.2 Products offered 259
13.1.9 OPTIBIOTIX HEALTH PLC 260
13.1.9.1 Business overview 260
13.1.9.2 Products offered 261
13.1.9.3 Recent developments 262
13.1.9.3.1 Product approvals 262
13.1.9.3.2 Deals 262
13.1.10 RESBIOTIC 263
13.1.10.1 Business overview 263
13.1.10.2 Products offered 263
13.1.10.3 Recent developments 264
13.1.10.3.1 Expansions 264
?
13.1.11 INFINANT HEALTH INC. 265
13.1.11.1 Business overview 265
13.1.11.2 Products offered 265
13.1.12 BIOGAIA AB 266
13.1.12.1 Business overview 266
13.1.12.2 Products offered 268
13.1.12.3 Recent developments 269
13.1.12.3.1 Deals 269
13.1.12.3.2 Expansions 269
13.1.13 EXEGI PHARMA, LLC 270
13.1.13.1 Business overview 270
13.1.13.2 Products offered 270
13.1.13.3 Recent developments 271
13.1.13.3.1 Deals 271
13.2 OTHER PLAYERS 272
13.2.1 AOBIOME 272
13.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD. 273
13.2.3 NUBIYOTA 274
13.2.4 OXTHERA AB 275
13.2.5 NEXBIOME 276
13.2.6 VEDANTA BIOSCIENCES, INC. 277
13.2.7 ENTEROME 278
13.2.8 APSEN FARMACEUTICA S.A. 279
13.2.9 METAGEN THERAPEUTICS, INC. 280
13.2.10 SNIPR BIOME 281
13.2.11 MAAT PHARMA SA 282
13.2.12 MIKROBIOMIK 283
14 APPENDIX 284
14.1 DISCUSSION GUIDE 284
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 287
14.3 CUSTOMIZATION OPTIONS 289
14.4 RELATED REPORTS 289
14.5 AUTHOR DETAILS 290
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 41
TABLE 2 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS 51
TABLE 3 EXAMPLES OF INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET 52
TABLE 4 LIST OF START-UPS/SMES IN HUMAN MICROBIOME MARKET 53
TABLE 5 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021-2023 60
TABLE 6 KEY CONFERENCES & EVENTS IN HUMAN MICROBIOME MARKET (2024-2025) 74
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 11 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS 83
TABLE 12 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS 85
TABLE 13 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS
ON BUYING PROCESS (%) 87
TABLE 14 MAJOR INVESTMENT AND FUNDING 90
TABLE 15 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 96
TABLE 16 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION,
2023-2030 (USD MILLION) 97
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 18 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 20 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 99
TABLE 21 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 99
TABLE 22 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 99
TABLE 23 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION,
2023-2030 (USD MILLION) 100
TABLE 24 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 25 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 26 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 27 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 102
TABLE 28 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 102
TABLE 29 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 102
TABLE 30 HUMAN MICROBIOME MARKET FOR SYNBIOTICS, BY REGION,
2023-2030 (USD MILLION) 103
TABLE 31 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 104
TABLE 32 EUROPE: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 104
TABLE 33 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 104
TABLE 34 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 105
TABLE 35 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 105
TABLE 36 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 105
TABLE 37 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 107
TABLE 38 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS
FOR INFECTIOUS DISEASES 108
TABLE 39 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES,
BY REGION, 2023-2030 (USD MILLION) 109
TABLE 40 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 110
TABLE 41 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 110
TABLE 42 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 110
TABLE 43 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 111
TABLE 44 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 111
TABLE 45 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 111
TABLE 46 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS,
BY REGION, 2023-2030 (USD MILLION) 112
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 113
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 113
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 113
TABLE 50 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 114
TABLE 51 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 114
TABLE 52 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 114
TABLE 53 HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY REGION, 2023-2030 (USD MILLION) 115
TABLE 54 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 115
TABLE 55 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 116
TABLE 56 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 116
TABLE 57 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 116
TABLE 58 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 117
TABLE 59 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 117
TABLE 60 HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 119
TABLE 61 HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY REGION, 2023-2030 (USD MILLION) 120
TABLE 62 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 120
TABLE 63 EUROPE: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 121
TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 121
TABLE 65 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 121
TABLE 66 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 122
TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),
BY COUNTRY, 2023-2030 (USD MILLION) 122
TABLE 68 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP),
BY REGION, 2023-2030 (USD MILLION) 123
TABLE 69 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 123
TABLE 70 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 124
TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 124
TABLE 72 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 124
TABLE 73 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 125
TABLE 74 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023-2030 (USD MILLION) 125
TABLE 75 OTHER MICROBIOME TYPES MARKET, BY REGION, 2023-2030 (USD MILLION) 126
TABLE 76 NORTH AMERICA: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 126
TABLE 77 EUROPE: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 127
TABLE 78 ASIA PACIFIC: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 127
TABLE 79 LATIN AMERICA: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 127
TABLE 80 MIDDLE EAST: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 128
TABLE 81 GCC COUNTRIES: OTHER MICROBIOME TYPES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 128
TABLE 82 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 130
TABLE 83 HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION,
BY REGION, 2023-2030 (USD MILLION) 131
TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 131
TABLE 85 EUROPE: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 131
TABLE 86 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 132
TABLE 87 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 132
TABLE 88 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 132
TABLE 89 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 133
TABLE 90 HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION,
BY REGION, 2023-2030 (USD MILLION) 133
TABLE 91 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 92 EUROPE: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 93 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 94 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 95 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 96 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 97 HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 137
TABLE 98 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2023-2030 (USD MILLION) 138
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 138
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 138
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 139
TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 139
TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 139
TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023-2030 (USD MILLION) 140
TABLE 105 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES,
BY REGION, 2023-2030 (USD MILLION) 141
TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 141
TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2023-2030 (USD MILLION) 141
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 142
TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 142
TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 142
TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 143
TABLE 112 HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY REGION, 2023-2030 (USD MILLION) 143
TABLE 113 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 144
TABLE 114 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 144
TABLE 115 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 144
TABLE 116 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 145
TABLE 117 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 145
TABLE 118 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 145
TABLE 119 HUMAN MICROBIOME MARKET, BY REGION, 2023-2030 (USD MILLION) 147
TABLE 120 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 149
TABLE 121 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 149
TABLE 122 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 149
TABLE 123 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 150
TABLE 124 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 150
TABLE 125 NORTH AMERICA: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 150
TABLE 126 NORTH AMERICA: MACROECONOMIC INDICATORS 151
TABLE 127 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 152
TABLE 128 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 152
TABLE 129 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 153
TABLE 130 US: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 153
TABLE 131 US: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 153
TABLE 132 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 154
TABLE 133 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 154
TABLE 134 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 155
TABLE 135 CANADA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 155
TABLE 136 CANADA: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 155
TABLE 137 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 156
TABLE 138 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 157
TABLE 139 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 157
TABLE 140 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 157
TABLE 141 EUROPE: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 158
TABLE 142 EUROPE: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 158
TABLE 143 EUROPE: MACROECONOMIC INDICATORS 159
TABLE 144 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 160
TABLE 145 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 160
TABLE 146 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2030 (USD MILLION) 160
TABLE 147 GERMANY: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 161
TABLE 148 GERMANY: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 161
TABLE 149 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 162
TABLE 150 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 162
TABLE 151 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 162
TABLE 152 UK: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 163
TABLE 153 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 163
TABLE 154 HUMAN MICROBIOME STARTUPS IN FRANCE 164
TABLE 155 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 164
TABLE 156 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 165
TABLE 157 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 165
TABLE 158 FRANCE: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 165
TABLE 159 FRANCE: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 166
TABLE 160 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 167
TABLE 161 ITALY: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 167
TABLE 162 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 167
TABLE 163 ITALY: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 168
TABLE 164 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 168
TABLE 165 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 169
TABLE 166 SPAIN: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 169
TABLE 167 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 169
TABLE 168 SPAIN: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 170
TABLE 169 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 170
TABLE 170 REST OF EUROPE: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 171
TABLE 171 REST OF EUROPE: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 171
TABLE 172 REST OF EUROPE: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 171
TABLE 173 REST OF EUROPE: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 172
TABLE 174 REST OF EUROPE: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 172
TABLE 175 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 174
TABLE 176 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 174
TABLE 177 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 174
TABLE 178 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 175
TABLE 179 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 175
TABLE 180 ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 175
TABLE 181 ASIA PACIFIC: MACROECONOMIC INDICATORS 176
TABLE 182 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 177
TABLE 183 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 177
TABLE 184 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 178
TABLE 185 CHINA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 178
TABLE 186 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 178
TABLE 187 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 179
TABLE 188 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 179
TABLE 189 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 180
TABLE 190 JAPAN: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 180
TABLE 191 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 180
TABLE 192 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 181
TABLE 193 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 181
TABLE 194 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 182
TABLE 195 INDIA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 182
TABLE 196 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 182
TABLE 197 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 183
TABLE 198 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY TYPE,
2023-2030 (USD MILLION) 184
TABLE 199 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2030 (USD MILLION) 184
TABLE 200 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 184
TABLE 201 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 185
TABLE 202 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 186
TABLE 203 AUSTRALIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 186
TABLE 204 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2030 (USD MILLION) 186
TABLE 205 AUSTRALIA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 187
TABLE 206 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 187
TABLE 207 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 188
TABLE 208 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 188
TABLE 209 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 188
TABLE 210 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 189
TABLE 211 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 189
TABLE 212 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 189
TABLE 213 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 190
TABLE 214 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY TYPE,
2023-2030 (USD MILLION) 190
TABLE 215 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2030 (USD MILLION) 190
TABLE 216 LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 191
TABLE 217 LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 191
TABLE 218 LATIN AMERICA: MACROECONOMIC INDICATORS 192
TABLE 219 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 192
TABLE 220 BRAZIL: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 193
TABLE 221 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 193
TABLE 222 BRAZIL: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 193
TABLE 223 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER,
2023-2030 (USD MILLION) 194
TABLE 224 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 194
TABLE 225 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 195
TABLE 226 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 195
TABLE 227 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 195
TABLE 228 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 196
TABLE 229 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 196
TABLE 230 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 197
TABLE 231 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 197
TABLE 232 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 197
TABLE 233 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 198
TABLE 234 MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 198
TABLE 235 MIDDLE EAST: MACROECONOMIC INDICATORS 199
TABLE 236 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 199
TABLE 237 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 199
TABLE 238 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 200
TABLE 239 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 200
TABLE 240 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 200
TABLE 241 GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 201
TABLE 242 SAUDI ARABIA: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 202
TABLE 243 SAUDI ARABIA: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 202
TABLE 244 SAUDI ARABIA: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 202
TABLE 245 SAUDI ARABIA: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 203
TABLE 246 SAUDI ARABIA: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 203
TABLE 247 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 204
TABLE 248 UAE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 204
TABLE 249 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 204
TABLE 250 UAE: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2023-2030 (USD MILLION) 205
TABLE 251 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2030 (USD MILLION) 205
TABLE 252 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 206
TABLE 253 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 206
TABLE 254 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 206
TABLE 255 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 207
TABLE 256 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 207
TABLE 257 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY PRODUCT, 2023-2030 (USD MILLION) 208
TABLE 258 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY TYPE, 2023-2030 (USD MILLION) 208
TABLE 259 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY DISEASE, 2023-2030 (USD MILLION) 208
TABLE 260 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 209
TABLE 261 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 209
TABLE 262 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 210
TABLE 263 AFRICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2030 (USD MILLION) 210
TABLE 264 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2030 (USD MILLION) 210
TABLE 265 AFRICA: HUMAN MICROBIOME MARKET,
BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 211
TABLE 266 AFRICA: HUMAN MICROBIOME MARKET,
BY END USER, 2023-2030 (USD MILLION) 211
TABLE 267 AFRICA: MACROECONOMIC INDICATORS 212
TABLE 268 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
IN HUMAN MICROBIOME MARKET 213
TABLE 269 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION 218
TABLE 270 HUMAN MICROBIOME MARKET: PRODUCT FOOTPRINT 223
TABLE 271 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT 224
TABLE 272 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT 225
TABLE 273 HUMAN MICROBIOME MARKET: REGION FOOTPRINT 226
TABLE 274 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES 228
TABLE 275 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF
KEY START UPS/SMES 229
TABLE 276 HUMAN MICROBIOME MARKET: PRODUCT APPROVALS,
JANUARY 2021-AUGUST 2024 233
TABLE 277 IMMUNOTHERAPY DRUGS MARKET: DEALS, JANUARY 2021-AUGUST 2024 234
TABLE 278 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: COMPANY OVERVIEW 235
TABLE 279 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: PRODUCTS OFFERED 236
TABLE 280 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: DEALS,
JANUARY 2021-MAY 2024 238
TABLE 281 SEED HEALTH, INC.: COMPANY OVERVIEW 240
TABLE 282 SEED HEALTH, INC.: PRODUCTS OFFERED 240
TABLE 283 SEED HEALTH, INC.: DEALS, JANUARY 2021-MAY 2024 241
TABLE 284 PENDULUM: COMPANY OVERVIEW 243
TABLE 285 PENDULUM: PRODUCTS OFFERED 244
TABLE 286 PENDULUM: DEALS, JANUARY 2021-MAY 2024 244
TABLE 287 SERES THERAPEUTICS: COMPANY OVERVIEW 246
TABLE 288 SERES THERAPEUTICS: PRODUCTS OFFERED 247
TABLE 289 SERES THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021-MAY 2024 247
TABLE 290 SERES THERAPEUTICS: DEALS, JANUARY 2021-MAY 2024 248
TABLE 291 FERRING PHARMACEUTICALS: COMPANY OVERVIEW 250
TABLE 292 FERRING PHARMACEUTICALS: PRODUCTS OFFERED 251
TABLE 293 FERRING PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021-MAY 2024 252
TABLE 294 FERRING PHARMACEUTICALS: DEALS, JANUARY 2021-MAY 2024 252
TABLE 295 BIOMEBANK: COMPANY OVERVIEW 254
TABLE 296 BIOMEBANK: PRODUCTS OFFERED 254
TABLE 297 BIOMEBANK: PRODUCT APPROVALS, JANUARY 2021-MAY 2024 255
TABLE 298 BIOMEBANK.: EXPANSIONS, JANUARY 2021-MAY 2024 255
TABLE 299 BIOHM HEALTH INC.: COMPANY OVERVIEW 256
TABLE 300 BIOHM HEALTH INC.: PRODUCTS OFFERED 256
TABLE 301 BIOHM HEALTH INC.: DEALS, JANUARY 2021-MAY 2024 258
TABLE 302 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW 259
TABLE 303 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED 259
TABLE 304 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW 260
TABLE 305 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED 261
TABLE 306 OPTIBIOTIX HEALTH PLC: PRODUCT APPROVALS, JANUARY 2021-MAY 2024 262
TABLE 307 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2021-MAY 2024 262
TABLE 308 RESBIOTIC: COMPANY OVERVIEW 263
TABLE 309 RESBIOTIC: PRODUCTS OFFERED 263
TABLE 310 RESBIOTIC: EXPANSIONS, JANUARY 2021-MAY 2024 264
TABLE 311 INFINANT HEALTH INC.: COMPANY OVERVIEW 265
TABLE 312 INFINANT HEALTH INC.: PRODUCTS OFFERED 265
TABLE 313 BIOGAIA AB: COMPANY OVERVIEW 266
TABLE 314 BIOGAIA AB: PRODUCTS OFFERED 268
TABLE 315 BIOGAIA AB: DEALS, JANUARY 2021-MAY 2024 269
TABLE 316 BIOGAIA AB: EXPANSIONS, JANUARY 2021-MAY 2024 269
TABLE 317 EXEGI PHARMA, LLC: COMPANY OVERVIEW 270
TABLE 318 EXEGI PHARMA, LLC: PRODUCTS OFFERED 270
TABLE 319 EXEGI PHARMA, LLC: DEALS, JANUARY 2021-MAY 2024 271
TABLE 320 AOBIOME: COMPANY OVERVIEW 272
TABLE 321 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 273
TABLE 322 NUBIYOTA: COMPANY OVERVIEW 274
TABLE 323 OXTHERA AB: COMPANY OVERVIEW 275
TABLE 324 NEXBIOME: COMPANY OVERVIEW 276
TABLE 325 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW 277
TABLE 326 ENTEROME: COMPANY OVERVIEW 278
TABLE 327 APSEN FARMACEUTICA S/A.: COMPANY OVERVIEW 279
TABLE 328 METAGEN THERAPEUTICS, INC.: COMPANY OVERVIEW 280
TABLE 329 SNIPR BIOME: COMPANY OVERVIEW 281
TABLE 330 MAAT PHARMA SA: COMPANY OVERVIEW 282
TABLE 331 MIKROBIOMIK: COMPANY OVERVIEW 283
FIGURE 1 RESEARCH DESIGN 33
FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 35
FIGURE 3 HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 36
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 37
FIGURE 5 ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES, INC.: REVENUE SHARE ANALYSIS (2023) 37
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 38
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 39
FIGURE 8 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS 40
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
FIGURE 10 HUMAN MICROBIOME MARKET, BY PRODUCT, 2024 VS. 2030 (USD MILLION) 44
FIGURE 11 HUMAN MICROBIOME MARKET, BY DISEASE, 2024 VS. 2030 (USD MILLION) 45
FIGURE 12 HUMAN MICROBIOME MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION) 45
FIGURE 13 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,
2024 VS. 2030 (USD MILLION) 46
FIGURE 14 HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 46
FIGURE 15 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 47
FIGURE 16 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT
TO DRIVE GROWTH 48
FIGURE 17 LIVE BIOTHERAPEUTIC PRODUCTS (LBP) SEGMENT TO ACCOUNT
FOR LARGEST MARKET SHARE IN 2023 49
FIGURE 18 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING
FORECAST PERIOD 49
FIGURE 19 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 50
FIGURE 20 COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS 55
FIGURE 21 HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMERS' BUSINESSES 58
FIGURE 22 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS,
BY KEY PLAYER (2023) 59
FIGURE 23 AVERAGE SELLING PRICE OF HUMAN MICROBIOME PRODUCTS, BY TYPE (2023) 60
FIGURE 24 AVERAGE SELLING PRICE OF HUMAN MICROBIOME PRODUCTS, BY REGION (2023) 61
FIGURE 25 HUMAN MICROBIOME PIPELINE, BY DISEASE 62
FIGURE 26 HUMAN MICROBIOME PIPELINE, BY PHASE 63
FIGURE 27 HUMAN MICROBIOME PIPELINE, BY REGION 63
FIGURE 28 PATENT APPLICATIONS FOR HUMAN MICROBIOME
(JANUARY 2013-DECEMBER 2023) 64
FIGURE 29 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 65
FIGURE 30 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 66
FIGURE 31 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS 67
FIGURE 32 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 69
FIGURE 33 IMPACT OF AI/GEN AI ON DEVELOPMENT & COMMERCIALIZATION
OF MICROBIOMES 70
FIGURE 34 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS 83
FIGURE 35 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS 84
FIGURE 36 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS
ON BUYING PROCESS 87
FIGURE 37 KEY BUYING CRITERIA OF END USERS 88
FIGURE 38 INVESTMENTS & FUNDING IN HUMAN MICROBIOME MARKET (2022-2023) 89
FIGURE 39 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 148
FIGURE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 173
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 216
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME
MARKET (2023) 217
FIGURE 43 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 221
FIGURE 44 HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT 222
FIGURE 45 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 227
FIGURE 46 EV/EBITDA OF KEY PLAYERS 230
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY PLAYERS 230
FIGURE 48 HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 231
FIGURE 49 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: COMPANY SNAPSHOT (2023) 236
FIGURE 50 SERES THERAPEUTICS: COMPANY SNAPSHOT (2023) 246
FIGURE 51 FERRING PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 251
FIGURE 52 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2023) 260
FIGURE 53 BIOGAIA AB: COMPANY SNAPSHOT (2023) 267
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security